Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1993 Mar;99:143–147. doi: 10.1289/ehp.9399143

Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.

S A Kyrtopoulos 1, V L Souliotis 1, C Valavanis 1, V A Boussiotis 1, G A Pangalis 1
PMCID: PMC1567067  PMID: 8319612

Abstract

O6-Methylguanine has been measured in peripheral blood leukocytes of 14 patients during one or more cycles of treatment with procarbazine (daily treatment for 10 days) and in 12 patients during one or more cycles of treatment with dacarbazine (single dose per cycle). Adduct formation at levels up to about 0.4 fmole/microgram DNA was detected in all procarbazine- and all but one dacarbazine-treated patients at some point after treatment. O6-Methylguanine accumulated during procarbazine treatment in a dose-related manner (mean rate of accumulation 2.8 x 10(-4) fmole/microgram DNA per mg/m2 dose) and appeared to approach a plateau by the end of the cycle (above 600 mg/m2 cumulative dose). The average rate of O6-methylguanine formation 2 hr after dacarbazine treatment was 11 +/- 8 x 10(-4) fmole/microgram DNA per mg/m2 dose. Individuals examined on more than one treatment cycle with either drug showed broadly similar methylation responses. The rate of adduct accumulation showed a nonsignificant, negative correlation with the pretreatment lymphocyte levels of the repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT) in the case of procarbazine and no correlation in the case of dacarbazine. No consistent lymphocyte AGT depletion was noted as a result of treatment with either drug. No correlation between O6-methylguanine formation and hematological toxicity was observed. In eight patients showing full remission after treatment with dacarbazine, the value of O6-methylguanine (averaged over all the cycles) was 0.252 +/- 0.120 fmole/microgram DNA while in four patients showing partial or no response it was 0.087 +/- 0.110 fmole/microgram DNA (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779–827. doi: 10.1146/annurev.bi.56.070187.004023. [DOI] [PubMed] [Google Scholar]
  2. Bartsch H., Montesano R. Relevance of nitrosamines to human cancer. Carcinogenesis. 1984 Nov;5(11):1381–1393. doi: 10.1093/carcin/5.11.1381. [DOI] [PubMed] [Google Scholar]
  3. Foiles P. G., Miglietta L. M., Akerkar S. A., Everson R. B., Hecht S. S. Detection of O6-methyldeoxyguanosine in human placental DNA. Cancer Res. 1988 Aug 1;48(15):4184–4188. [PubMed] [Google Scholar]
  4. Fong L. Y., Jensen D. E., Magee P. N. DNA methyl-adduct dosimetry and O6-alkylguanine-DNA alkyl transferase activity determinations in rat mammary carcinogenesis by procarbazine and N-methylnitrosourea. Carcinogenesis. 1990 Mar;11(3):411–417. doi: 10.1093/carcin/11.3.411. [DOI] [PubMed] [Google Scholar]
  5. Gibson N. W., Hartley J., La France R. J., Vaughan K. Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis. 1986 Feb;7(2):259–265. doi: 10.1093/carcin/7.2.259. [DOI] [PubMed] [Google Scholar]
  6. Hecht S. S., Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv. 1989;8(2):273–294. [PubMed] [Google Scholar]
  7. Hotchkiss J. H. Preformed N-nitroso compounds in foods and beverages. Cancer Surv. 1989;8(2):295–321. [PubMed] [Google Scholar]
  8. Kaldor J. M., Day N. E., Shiboski S. Epidemiological studies of anticancer drug carcinogenicity. IARC Sci Publ. 1986;(78):189–201. [PubMed] [Google Scholar]
  9. Lee S. M., Thatcher N., Margison G. P. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res. 1991 Jan 15;51(2):619–623. [PubMed] [Google Scholar]
  10. Meer L., Janzer R. C., Kleihues P., Kolar G. F. In vivo metabolism and reaction with DNA of the cytostatic agent, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem Pharmacol. 1986 Oct 1;35(19):3243–3247. doi: 10.1016/0006-2952(86)90419-3. [DOI] [PubMed] [Google Scholar]
  11. Pedersen-Bjergaard J., Specht L., Larsen S. O., Ersbøll J., Struck J., Hansen M. M., Hansen H. H., Nissen N. I. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987 Jul 11;2(8550):83–88. doi: 10.1016/s0140-6736(87)92744-9. [DOI] [PubMed] [Google Scholar]
  12. Rossi S. C., Conrad M., Voigt J. M., Topal M. D. Excision repair of O6-methylguanine synthesized at the rat H-ras N-methyl-N-nitrosourea activation site and introduced into Escherichia coli. Carcinogenesis. 1989 Feb;10(2):373–377. doi: 10.1093/carcin/10.2.373. [DOI] [PubMed] [Google Scholar]
  13. Souliotis V. L., Boussiotis V. A., Pangalis G. A., Kyrtopoulos S. A. In vivo formation and repair of O6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. Carcinogenesis. 1991 Feb;12(2):285–288. doi: 10.1093/carcin/12.2.285. [DOI] [PubMed] [Google Scholar]
  14. Souliotis V. L., Kaila S., Boussiotis V. A., Pangalis G. A., Kyrtopoulos S. A. Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res. 1990 May 1;50(9):2759–2764. [PubMed] [Google Scholar]
  15. Souliotis V. L., Kyrtopoulos S. A. A novel, sensitive assay for O6-methyl- and O6-ethylguanine in DNA, based on repair by the enzyme O6-alkylguanine-DNA-alkyltransferase in competition with an oligonucleotide containing O6-methylguanine. Cancer Res. 1989 Dec 15;49(24 Pt 1):6997–7001. [PubMed] [Google Scholar]
  16. Umbenhauer D., Wild C. P., Montesano R., Saffhill R., Boyle J. M., Huh N., Kirstein U., Thomale J., Rajewsky M. F., Lu S. H. O(6)-methyldeoxyguanosine in oesophageal DNA among individuals at high risk of oesophageal cancer. Int J Cancer. 1985 Dec 15;36(6):661–665. doi: 10.1002/ijc.2910360607. [DOI] [PubMed] [Google Scholar]
  17. Valagussa P., Santoro A., Fossati Bellani F., Franchi F., Banfi A., Bonadonna G. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood. 1982 Mar;59(3):488–494. [PubMed] [Google Scholar]
  18. Wiestler O. D., Kleihues P., Rice J. M., Ivankovic S. DNA methylation in maternal, fetal and neonatal rat tissues following perinatal administration of procarbazine. J Cancer Res Clin Oncol. 1984;108(1):56–59. doi: 10.1007/BF00390973. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES